SYBX - Synlogic, Inc.

Synlogic, Inc.

301 Binney Street
Suite 402
Cambridge, MA 02142
United States
617-401-9975
http://www.synlogictx.com

Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 74

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Peter Barrett	Exec. Chairman	25.15k	N/A	1953
Dr. José Carlos Gutierrez-Ramos Ph.D.	Advisor	817.27k	N/A	1963
Dr. Aoife M. Brennan MB, BCh, BAO, MMSc	Pres, CEO, Chief Medical Officer & Director	N/A	N/A	1976
Prof. Timothy K. Lu	Co-Founder	N/A	N/A	N/A
Dr. James J. Collins	Co-Founder	N/A	N/A	N/A

Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Corporate Governance

Synlogic, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.